| pubmed-article:20943374 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C0239307 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C1513822 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C1880171 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C1456649 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C0205208 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C0069717 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C1136080 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:20943374 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:20943374 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:20943374 | pubmed:dateCreated | 2011-1-3 | lld:pubmed |
| pubmed-article:20943374 | pubmed:abstractText | To assess objective response rates after 4 cycles of gemcitabine in combination with oxaliplatin in children and adolescents with relapsed or refractory solid tumours. | lld:pubmed |
| pubmed-article:20943374 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20943374 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20943374 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20943374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20943374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20943374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20943374 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20943374 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20943374 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:20943374 | pubmed:issn | 1879-0852 | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:VHH | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:ColosimoCesar... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:GeoergerBirgi... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:VassalGillesG | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:BoosJoachimJ | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:LeblondPierre... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:DiasNathalieN | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:CouanetDomini... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:FrappazDidier... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:AertsIsabelle... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:ChisholmJulia... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:JaspanTimothy... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:GentetJean-Cl... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:HainSharonS | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:ZwaanChristia... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:Le... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:Mc... | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:DevosAnnickA | lld:pubmed |
| pubmed-article:20943374 | pubmed:author | pubmed-author:European... | lld:pubmed |
| pubmed-article:20943374 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:20943374 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20943374 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:20943374 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20943374 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20943374 | pubmed:pagination | 230-8 | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:meshHeading | pubmed-meshheading:20943374... | lld:pubmed |
| pubmed-article:20943374 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20943374 | pubmed:articleTitle | Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. | lld:pubmed |
| pubmed-article:20943374 | pubmed:affiliation | Institut Gustave Roussy, Université Paris-Sud, 39 rue Camille Desmoulins, 94805 Villejuif, France. geoerger@igr.fr | lld:pubmed |
| pubmed-article:20943374 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20943374 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:20943374 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:20943374 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
